is compound tirzepatide fda approved confirms shortage still over, gives compounders a grace period Compounded Semaglutide & Tirzepatide 2025:

Increase by 2.5mg every four weeks as tolerated

SURMOUNT-1 results In this 72-week obesity trial, participants receiving tirzepatide achieved remarkable weight loss results: 5 mg dose: 85% achieved at least 5% weight reduction, with average weight loss of 15% 10 mg dose: 89% achieved at least 5% weight reduction, with average weight loss of 19% 15 mg dose: 91% achieved at least 5% weight reduction, with average weight loss of 21% These results were achieved with consistent weekly dosing

This forceful stream can damage the fragile peptide chains

doi: 10.3390/jcm12010145

It enrolled 751 adults and ran for 72 weeks at the maximum tolerated dose of each drug